ReLive: investigators meeting and E-poster of the study design during the 2015 EASL congress
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that an investigators’ meeting (on April 24, 2015) will be held during the 50th annual meeting of the European Association for the Study of the Liver (EASL) taking place in Vienna (Austria) from April 22 to April 26, 2015, with ReLive investigators.
The EASL was founded almost 50 years ago to promote and exchange science in the field of liver diseases. Its annual meeting involves the specialists of hepatology and liver cancer and is therefore a choice opportunity to gather the European and US investigators of the ReLive clinical trial who will attend the congress.
At this occasion, an investigators meeting will take place with the clinicians involved in ReLive trial in order to review study advancement, share views and allow open discussions.
Besides, the ReLive study design, Livatag® phase III clinical trial, will be published as an e-poster during the 50th annual meeting of the European Association for the Study of the Liver (EASL), enhancing the awareness of the scientific community about ReLive and Livatag®.